[
  {
    "criterion": "Provides a brief summary of managing tardive dyskinesia in a 62-year-old patient on haloperidol for over 10 years referencing the 2023 American Psychiatric Association guidelines",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Incorrectly states that switching to second-generation antipsychotics or adding a VMAT2 inhibitor is the only effective treatment for tardive dyskinesia",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Seeks clarification from the user about their specific treatment plan and symptoms before providing a summary",
    "axis": "context_awareness",
    "point": 6
  },
  {
    "criterion": "Responds in a clear, concise, and natural language, avoiding technical jargon",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Fails to mention the importance of monitoring the patient's symptoms and adjusting their treatment plan as needed",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "States that the 2023 American Psychiatric Association guidelines are the most up-to-date and relevant resource for managing tardive dyskinesia",
    "axis": "accuracy",
    "point": 7
  },
  {
    "criterion": "Asks the user if they have any specific questions or concerns about their treatment plan before providing a summary",
    "axis": "instruction_following",
    "point": 5
  },
  {
    "criterion": "Incorrectly states that haloperidol is not effective in treating tardive dyskinesia",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a detailed explanation of the benefits and risks of switching to second-generation antipsychotics or adding a VMAT2 inhibitor",
    "axis": "completeness",
    "point": 10
  }
]